Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. (21st September 2022)

• Record Type: Journal Article
• Authors: Jadoon, Sarmad Sheraz; Ilyas, Umair; Zafar, Hajra; Paiva-Santos, Ana Cláudia; Khan, Saifullah; Khan, Saeed Ahmad; Ahmed, Tanzeel; Rasool, Yasir; Altaf, Reem; Raza, Faisal; Abbas, Muhammad
• Other Names: Deng Mingming Academic Editor.
• Is Part Of: Journal of oncology. Volume 2022(2022)
• Publication Date: 2022-09-21
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2022/4022960
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Glioblastoma multiforme is a serious and life-threatening tumor of central nervous system, characterized by aggressive behavior, poor prognosis, and low survival rate. Despite of the availability of aggressive antitumor therapeutic regimen for glioblastoma (radiotherapy followed by chemotherapeutic dose), recovery rate, and patients' survival ratio is attributed to the lack of selectivity of therapeutic drugs and less advancement in cancer therapeutics over last decade. Moreover, tools employed in conventional diagnosis of glioblastoma are more invasive and painful, making the process excruciating for the patients. These challenges urge for the need of novel biomarkers for diagnosis, prognosis, and prediction purpose with less invasiveness and more patient compliance. This article will explore the genetic biomarkers isocitrate dehydrogenase mutation, MGMT mutations, and EGFR that can be deployed as an analytical tool in diagnosis of disease and prognosis of a therapeutic course. The review also highlights the importance of employing novel microRNAs as prognostic biomarkers. Recent clinical advancements to treat GBM and to prevent relapse of the disease are also discussed in this article in the hope of finding a robust and effective method to treat GBM.